Accufydx

This startup develops NGS tagging library preparation technology for efficient DNA molecule tagging. Their technology enhances MRD analysis on liquid biopsy samples via NGS, offering high sensitivity, rapid sample preparation, and preservation of both epigenetic and genetic information.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Current methods for detecting measurable residual disease (MRD) and analyzing liquid biopsies using next-generation sequencing (NGS) lack the sensitivity and specificity needed for accurate tumor DNA detection. Existing NGS sample preparation techniques often fail to preserve both genetic and epigenetic information, limiting comprehensive multiomic analysis. Gene fusion and copy number abnormality detection via ctDNA MRD monitoring also suffers from low sensitivity.

Solution

Accufy Diagnostics offers NGS tagging library preparation and target enrichment technologies designed to enhance MRD analysis using liquid biopsy samples. Their solutions improve the sensitivity of NGS assays, enabling more accurate detection of circulating tumor DNA (ctDNA). The Accufy NGS tagging library preparation technology efficiently tags ctDNA molecules, maximizing the ratio of DNA molecules with unique molecular barcodes readable by NGS. The Accufy NGS target enrichment technology selectively enriches target DNA molecules while preserving multiomic information, allowing for simultaneous detection of ctDNA methylation profiles and mutation profiles. These technologies can be integrated with existing NGS workflows or used as a complete multiomic NGS solution.

Target Audience

The primary target audience includes clinical diagnostic labs, researchers, and pharmaceutical companies involved in MRD analysis, liquid biopsy, and multiomic NGS-based disease studies.

Features

NGS tagging library preparation technology for efficient ctDNA molecule tagging with a high ratio of uniquely barcoded molecules.
NGS target enrichment technology for selective enrichment of target DNA, preserving genetic and epigenetic information.
Enables a 1-log improvement in sensitivity, reaching 0.001% variant allele fraction (VAF) or better.
Short sample preparation time of approximately 4 hours.
Compatible with existing NGS sample preparation and target enrichment technologies.
Facilitates multiomic NGS analysis, including ctDNA methylation and mutation profiling.
Addresses the need for operation ease in clinical diagnostic labs.